With 1 in 4 people affected by mental or neurological disorders, our aim is to become the first life sciences company to bring a psilocybin drug to market targeting Major Depressive Disorder (MDD). 


Cybin is a leading Life Sciences Company focused on psychedelic drug development, unique delivery mechanisms, improved novel compounds and protocols that target psychiatric and neurological conditions.

PsiloTec will become the

premier global supplier of high-quality organic therapy mushrooms,

containing psilocybin and other

active compounds.

It will also demonstrate

effectiveness in many conditions,

and support widespread

therapeutic use.

Psilocybin (found in “magic mushrooms”) is a psychedelic compound that works by activating serotonin receptors and impacts mood, cognition, and perception. Psilocybin is not naturally addictive and has been used for thousands of years for both spiritual

and medicinal impacts.

Scientific & Digital Health Advisory Committees